Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRM-ACT: EDP/M vs Sz/M in Advanced Adrenocortical Carcinoma
NCT00094497Phase 3Completed
- Sponsor
- Collaborative Group for Adrenocortical Carcinoma Treatment
- Start
- Jun 2004
- Primary completion
- Dec 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 8
01
Overview
A Phase 3 trial of etoposide, doxorubicin, cisplatin, streptozocin, mitotane in adrenocortical carcinoma (ACC), sponsored by Collaborative Group for Adrenocortical Carcinoma Treatment. Started Jun 2004; status: completed.
02
Drugs
etoposidedoxorubicincisplatinstreptozocinmitotane
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT00094497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094497.